Is Cancer Quackery Dead?

The amount of money wasted on cancer quackery is unknown but probably exceeds one billion dollars per year -- the amount spent for cancer research.

According to Dr. Jarvis is Professor of Public Health and Preventive Medicine, School of Medicine and Public Health, Loma Linda University, and President of the National Council Against Health Fraud, some of the worst quackery-related tragedies result from delay or failure to act. An example of a needless death involved an Oregon man who treated his basal cell carcinoma of the mouth with a mail-order remedy for 15 years. What makes this case especially tragic is that since this type of cancer almost never metastasizes, he had many years in which to correct his folly. Although badly disfigured by the growing tumor, he continued self-treatment.

Overreliance upon dietary treatment is a common means by which indirect harm kills cancer sufferers. A health food store owner discovered a lump in her breast. After diagnosing it as cancer, she boasted to her health food friends that she was "going to prove once and for all that diet cure works!" Unfortunately, although at least 80% of self-discovered breast lumps are benign, hers was cancerous. Her husband looked after her for more than a year before the lesion became so gross and her pain so unbearable that she asked to be taken to a doctor for the first time. She died five days later.

For more information, go to http://www.quackwatch.com/

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap